The liver is one of the most frequent locations for distant metastases in breast cancer patients, and breast cancer is the primary reason for cancerrelated deaths in women globally. There are few therapeutic choices available for patients with breast cancer liver metastases, and drug resistance is common, which results in a bad prognosis and a short survival. Immunotherapy has a very poor therapeutic effect on liver metastases, and they are also resistant to chemotherapy and targeted therapies. Consequently, it is essential to comprehend the mechanisms of medication resistance in patients with breast cancer liver metastases in order to create and optimise treatment methods as well as to investigate alternative therapeutic options. We outline current developments in the study of drug resistance mechanisms in breast cancer liver metastases in this review and talk about the therapeutic potential of these mechanisms to enhance patient prognoses and outcomes.
